BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
64.19
+1.31 (2.09%)
Biomarin Pharmaceuticals is a biotechnology company that specializes in developing and commercializing innovative therapies for rare genetic disorders and critical diseases
The company focuses on creating treatments for patients with serious and life-threatening conditions, often targeting specific genetic mutations. Biomarin’s research and product development emphasize precision medicine, with a commitment to advancing therapeutic options and improving the quality of life for individuals affected by these rare diseases. Through its work, Biomarin strives to address unmet medical needs and enhance patient care through scientific innovation.
NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation.
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?
CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.
WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it has entered into an agreement with Alexion, AstraZeneca Rare Disease for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate), a drug candidate for Wilson disease that Alexion has progressed through a Phase 3 clinical trial that met its primary endpoint. Monopar will be responsible for all future global development and commercialization activities.
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential medications.
